arrow
M

Mario Pirisi

Università del Piemonte Orientale
H指数:50
被引数:1.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Higher 25(OH)D Levels at Admission Predict a Favorable Disease Evolution in Moderate-to-Severe COVID-19 Patients

入院时较高水平的25(OH)D可预测中重度COVID-19患者疾病向良好方向发展

2026-04-160
OAAI
Lenvatinib versus sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: the LEVIATHAN Study

伦伐替尼对比索拉非尼作为阿替利珠单抗联合贝伐珠单抗后肝癌的二线治疗:LEVIATHAN 研究

2025-09-230
OAAI
The Medical Impact of Hepatitis D Virus Infection in Natives and Immigrants: The Italian Paradigm

乙型肝炎病毒感染对原住民和移民的医疗影响:意大利范例

2025-07-290
OAAI
Higher Serum Monolaurin Is Associated with a Lower Risk of COVID-19: Results from a Prospective Observational Cohort Study

血清单月桂酸水平较高与COVID-19风险降低相关:一项前瞻性观察性队列研究的结果

2025-03-101
OA
Extracellular Vesicles as a Potential Biomarker of Pulmonary Arterial Hypertension in Systemic Sclerosis
2025-02-141
OAAI
Post-COVID-19 sequelae are associated with sustained SARS-CoV-2-specific CD4+immune responses

后COVID-19后遗症与持续的SARS-CoV-2特异性CD4+免疫反应相关

2025-02-010
PRE
Lower Circulating Gas6 Levels Are Associated with Bulbar Phenotype and Faster Disease Progression in Amyotrophic Lateral Sclerosis Patients

低循环气体6水平与延髓症状及肌萎缩侧索硬化症患者疾病进展加速相关

2025-01-060
PRE
Chronic Hepatitis C Infection Treated with Direct-Acting Antiviral Agents and Occurrence/Recurrence of Hepatocellular Carcinoma: Does It Still Matter?
2024-12-100
OAAI
Delivering adjuvant and neoadjuvant treatments in the early stages of hepatocellular carcinoma

在肝细胞癌的早期阶段提供辅助和新辅助治疗

2024-10-223
OAAI
Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment

肝功能失代偿是使用阿特珠单抗联合贝伐单抗治疗的肝细胞癌患者死亡率的主要驱动因素: 成功抗病毒治疗的影响

2024-07-195
PRE